It comes from United States Pharmacopeia General Chapter 797, which sets a default beyond-use date for opened multi-dose vials of any kind
2036-A DEVELOPMENT OF A NOVEL CLINICAL SCREENING TOOL TO PREDICT LIVER FIBROSIS Madeleine Haff 1 , Na Wang 2 , Emily Kate Sisson 2 and Michelle Long 1,3 , (1)Boston Medical Center, Boston, MA, (2)Boston University, (3)Novo Nordisk Background: Nonalcoholic fatty liver disease (NAFLD) is a major contributor to liver disease in the United States, and non-invasive tools such as vibration-controlled transient elastography (VCTE) estimate the risk of liver fibrosis and help guide patient care
BPC works with your body to shore up normal digestive function.*
N-acetylcysteine therapy may be more robust by increasing bioavailability, e.g., by using N-acetylcysteine amide (Hara et al., Table 3 Clinical trials involving N-acetylcysteine in Alzheimers disease (AD) and mild-cognitive impairment (MCI)
At 200 mcg per dose, that is only 10 doses per vial